Drugs / MVA.tHIVconsv3
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05604209 | Oct 2022 → Sep 2024 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT04553016 | Aug 2021 → Nov 2022 | HIV infectious disease | University of Oxford | Unknown | No outcome recorded |
| Phase 1 | NCT04586673 | Jul 2021 → Aug 2022 | HIV infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT03844386 | Apr 2019 → Nov 2021 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA.tHIVconsv3 | “The vaccine was administered as ChAdOx1.tHIVconsv1 (C1) followed by MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) in regimen C1-M3M4.” PMID 40388952 ↗ May 2025 |
| Modality | Vaccine | “Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised,...” PMID 40388952 ↗ May 2025 |
| Route | Intramuscular | “The vaccine and placebo doses will be administered to all participants as an IM (intramuscular) injection in the deltoid muscle of the non-dominant arm” NCT03844386 ↗ |